Solid Malignancies Clinical Trial
Official title:
A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid
malignancies consists of two parts:
1. Single Dose Period - will characterise the absorption, metabolism, excretion and
pharmacokinetics of a single oral dose of [14C]AZD2014 from the body
2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour
activity of multiple doses of AZD2014 when given as a monotherapy or given in
combination with paclitaxel or fulvestrant.
This is a Phase I, open label, single centre, non-randomised study in patients with advanced
solid malignancies that is refractory or resistant to standard treatment or where no suitable
effective standard treatment exists or for whom paclitaxel or fulvestrant are appropriate
treatment choices. The study will be divided in two parts:
1. Single Dose Period - will enrol up to 6 evaluable patients to characterise the
absorption, metabolism, excretion and pharmacokinetics of a single radiolabelled [14C]
oral dose of 125mg AZD2014 via residential intensive PK sampling over 8 days. An
evaluable patient is defined as patient who does not vomit within 2 hours post dose and
who has completed the scheduled PK sampling.
2. Multiple Dose Period - patients who have completed the Single Dose Period may continue
to receive treatment as outpatients. Patients will be allocated to different treatment
regimes as decided between Investigator and patient on a risk / benefit basis. From Day
1, Cycle 1, non-radiolabelled AZD2014 treatment will be administered as oral tablets to
patients, either as:
i. 50mg BD monotherapy ii. 125mg BD taken on first 2 days of treatment each week in
combination with 500mg intramuscular fulvestrant on Day 1, Cycle 1, Day 15, Cycle 1; Day 1,
Cycle 2, then Day 1 of each monthly cycle thereafter iii. 50mg BD taken on first 3 days of
treatment each week for 6 weeks in combination with a single weekly paclitaxel infusion
(80mg/m2 ) followed by a one week break from treatment where no AZD2014 or paclitaxel will be
given. This 7 week schedule composes one cycle of treatment. Patients will be given up to 6
cycles of paclitaxel, although additional cycles of paclitaxel may be given if deemed
appropriate by the Investigator.
Radiolabelled AZD2014 will be administered to fasted patients (i.e. no food 2 hours before
and 1 hour after each dose). Non-radiolabelled AZD2014 will be administered either under
fasted or non-fasted conditions. The safety and tolerability and anti-tumour activity of
AZD2014 and combination with paclitaxel or fulvestrant will be evaluated in all enrolled
patients respectively using conventional safety parameters, AEs/SAEs and RECIST 1.1.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01202370 -
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
Completed |
NCT00162136 -
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
|
Phase 1 | |
Recruiting |
NCT05006794 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02537418 -
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
|
Phase 1 | |
Completed |
NCT01540526 -
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
|
Phase 1 | |
Completed |
NCT00033202 -
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
Completed |
NCT05866354 -
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00695370 -
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
|
Phase 2 | |
Completed |
NCT02325739 -
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
|
Phase 1/Phase 2 | |
Completed |
NCT00676299 -
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
|
Phase 1 | |
Active, not recruiting |
NCT00090727 -
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT01112397 -
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT00751894 -
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
|
Phase 2 |